AnHeart Therapeutics Revenue and Competitors

Shanghai, NY USA

Location

#6629

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • AnHeart Therapeutics's estimated annual revenue is currently $7.1M per year.(i)
  • AnHeart Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • AnHeart Therapeutics has 46 Employees.(i)
  • AnHeart Therapeutics grew their employee count by 44% last year.

AnHeart Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder & CMOReveal Email/Phone
2
Chief Corporate Affairs OfficerReveal Email/Phone
3
VP, Head US Medical AffairsReveal Email/Phone
4
VP Clinical Operations (U.S)Reveal Email/Phone
5
SVP & Head Clinical Development StrategyReveal Email/Phone
6
SVP, Head Global Clinical PharmacologyReveal Email/Phone
7
SVP & Head Global Regulatory AffairsReveal Email/Phone
8
VP, U.S. CommercialReveal Email/Phone
9
Director Clinical OperationsReveal Email/Phone
10
Medical DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is AnHeart Therapeutics?

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.

keywords:N/A

N/A

Total Funding

46

Number of Employees

$7.1M

Revenue (est)

44%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.8M462%N/A
#2
$5.5M477%N/A
#3
$5.5M470%N/A
#4
$2.7M47N/AN/A
#5
$7.4M48-8%N/A